Dr. Lal PathLabs Limited (IN:LALPATHLAB)
:LALPATHLAB
Want to see IN:LALPATHLAB full AI Analyst Report?
LALPATHLAB Stock Chart & Stats
₹1472.95
-₹106.10(-3.42%)
At close: 4:00 PM EST
₹1472.95
-₹106.10(-3.42%)
Day’s Range― - ―
52-Week Range₹1,272.00 - ₹1,771.30
Previous CloseN/A
Volume152.98K
Average Volume (3M)3.61K
Market Cap
₹236.06B
Enterprise Value₹230.82B
Total Cash (Recent Filing)₹13.02B
Total Debt (Recent Filing)₹2.55B
Price to Earnings (P/E)68.4
Beta0.59
Next Earnings
Apr 30, 2026EPS Estimate
7.25Next Dividend Ex-DateN/A
Dividend Yield0.89%
Share Statistics
EPS (TTM)6.70
Shares Outstanding167,555,020
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio1.15
Price to Book (P/B)9.21
Price to Sales (P/S)8.13
P/FCF Ratio38.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,577.00Price Target Upside7.06% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)35.33
Revenue Forecast (FY)₹30.57B
Bulls Say, Bears Say
Bulls Say
Strong Margins & ProfitabilityHigh gross and net margins indicate durable pricing power and efficient cost structure in diagnostic services. Sustained margins support reinvestment in labs and quality controls, help absorb pricing pressure, and enable consistent profit conversion as revenue scales over the next several quarters.
Robust Cash Generation And FCF GrowthConsistent operating cash flow growth aligned with net income and rising free cash flow shows the business converts earnings into liquidity. This durability underpins capital allocation flexibility for expansion, technology upgrades, dividends or M&A without stressing the balance sheet.
Conservative Balance Sheet, Low LeverageA low leverage profile and strong equity base provide resilience to demand volatility and reduce refinancing risk. This conservative structure supports strategic network expansion or counter-cyclical investment, preserving long-term operational flexibility and credit optionality.
Bears Say
Moderate Top-line Growth RateRevenue growth near ~10.8% is positive but moderate for a high-opportunity diagnostics market. Sustained mid-single-digit to low-double-digit organic growth may constrain scale-driven margin expansion and market share gains unless augmented by faster network roll-outs or inorganic deals.
Return On Equity Needs ImprovementAn ROE that lags potential suggests capital is not optimally deployed relative to shareholder equity. Even with strong margins and cash flow, suboptimal ROE can limit long-term shareholder returns unless management increases asset efficiency or pursues higher-return investments.
Limited Disclosure On Revenue Mix And ContractsLack of detailed segment mix and contract information creates structural uncertainty around customer concentration and pricing exposure. This opacity makes it harder to assess durability of margins and revenue under reimbursement or contract renegotiation risks over the medium term.
Dr. Lal PathLabs Limited News
LALPATHLAB FAQ
What was Dr. Lal PathLabs Limited’s price range in the past 12 months?
Dr. Lal PathLabs Limited lowest stock price was ₹1272.00 and its highest was ₹1771.30 in the past 12 months.
What is Dr. Lal PathLabs Limited’s market cap?
Dr. Lal PathLabs Limited’s market cap is ₹236.06B.
When is Dr. Lal PathLabs Limited’s upcoming earnings report date?
Dr. Lal PathLabs Limited’s upcoming earnings report date is Apr 30, 2026 which is in 2 days.
How were Dr. Lal PathLabs Limited’s earnings last quarter?
Dr. Lal PathLabs Limited released its earnings results on Jan 30, 2026. The company reported ₹6.7 earnings per share for the quarter, missing the consensus estimate of ₹7.625 by -₹0.925.
Is Dr. Lal PathLabs Limited overvalued?
According to Wall Street analysts Dr. Lal PathLabs Limited’s price is currently Undervalued.
Does Dr. Lal PathLabs Limited pay dividends?
Dr. Lal PathLabs Limited pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.89%. See more information on Dr. Lal PathLabs Limited dividends here
What is Dr. Lal PathLabs Limited’s EPS estimate?
Dr. Lal PathLabs Limited’s EPS estimate is 7.25.
How many shares outstanding does Dr. Lal PathLabs Limited have?
Dr. Lal PathLabs Limited has 167,555,020 shares outstanding.
What happened to Dr. Lal PathLabs Limited’s price movement after its last earnings report?
Dr. Lal PathLabs Limited reported an EPS of ₹6.7 in its last earnings report, missing expectations of ₹7.625. Following the earnings report the stock price went up 0.946%.
Which hedge fund is a major shareholder of Dr. Lal PathLabs Limited?
Currently, no hedge funds are holding shares in IN:LALPATHLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited provides diagnostic and related healthcare tests and services in India and internationally. It operates laboratories for carrying the pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The company also offers lab staff training; technical; and lab management services. As of March 31, 2022, the company had 277 clinical laboratories, including National Reference Lab at Delhi and Regional Reference Lab at Kolkata; and 4,731 patient service centers and 10,599 pick-up points. Dr. Lal PathLabs Limited was founded in 1949 and is based in Gurugram, India.
LALPATHLAB Stock 12 Month Forecast
Average Price Target
₹1,577.00
▲(7.06% Upside)
Technical Analysis
Krsnaa Diagnostics Limited
―
Metropolis Healthcare Ltd.
―
Thyrocare Technologies Ltd
―
Vijaya Diagnostic Centre Ltd.
―
Vimta Labs Limited
―